Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis
- First Online:
- 444 Downloads
Infliximab has been shown to be efficacious in acute exacerbations of ulcerative colitis (UC).
To evaluate the cost-effectiveness of infliximab treatment in patients hospitalised with acute exacerbations of UC.
A decision analysis model was constructed to simulate the progression of acute UC patients treated with infliximab induction regimen over 1 year. Infliximab treatment was compared with standard care, ciclosporin and surgery using transitions derived from infliximab and ciclosporin randomised trials. Costs and outcomes were discounted at 3.5%. Intermediate outcomes of colectomy and post-surgery complications were translated into the primary effectiveness measurement, which was quality-adjusted life years (QALYs) estimated using EQ-5D. One-way and probabilistic sensitivity analyses were performed to estimate the uncertainty around the results.
The incremental cost effectiveness ratio (ICER) for infliximab was £19,545 per QALY compared to ciclosporin, which in turn dominated standard care. Sensitivity analysis indicated patient body weight, utility estimates and treatment effect of alternative treatment strategies to be the most important factors affecting cost-effectiveness.
Infliximab induction regimen appears to be a cost-effective treatment option for UC patients hospitalised with an acute exacerbation.
KeywordsCost effectiveness Acute Ulcerative colitis Infliximab
- 2.Jarnerot, G., Rolny, P., Sandberg-Gertzen, H.: Intensive intravenous treatment of ulcerative colitis. Gastroenterology 89(5), 1005–1013 (1985)Google Scholar
- 4.Leiper, K., Lowe, D., Driscoll, R., et al.: UK IBD audit 2006: National results for the organisation and process of IBD care in the UK. Published 2007; available at http://www.rcplondon.ac.uk/college/ceeu/ceeu_uk_ibd_audit_2006.pdf
- 15.Reference costs 2006/07: National schedule of reference costs. Department of Health. January 2008Google Scholar
- 16.Woehl, A., Hawthorne, B., Morgan, C., Punekar, Y., McEwan, P.: The epidemiology and healthcare resource use in patients with Crohn’s disease: a population based UK study. Value Health 10(6), A355 (2007)Google Scholar
- 20.National Institute of Health and Clinical Excellence (NICE): Guide to the Methods of Technology Appraisal (reference NO515). NICE, London, (2004), http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf
- 22.National Institute of Health and Clinical Excellence (NICE). Guidance on the Use of Infliximab for Psoriasis. London: Technology Appraisal Guidance 134, January (2008), http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Guidelines/NICE-guidance-on-the-use-of-infliximab-for-the-treatment-of-psoriasis/
- 23.Laharie, D.: A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF). Clinicaltrials.gov identifier–NCT00542152, http://clinicaltrials.gov/ct2/show/NCT00542152